Zomedica Corp. [AMEX: ZOM] loss -3.32% on the last trading session, reaching $0.61 price per share at the time. The company report on July 6, 2021 that Zomedica Provides Corporate Update.
FOCUSED ON TRUFORMA® INSTRUMENT PLACEMENTS AND BUILDING DIRECT SALES ORGANIZATION.
Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update:.
Zomedica Corp. represents 977.81 million in outstanding shares, while the company has a total market value of $572.69 million with the latest information. ZOM stock price has been found in the range of $0.60 to $0.66.
If compared to the average trading volume of 40.11M shares, ZOM reached a trading volume of 23391921 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $1.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Zomedica Corp. is set at 0.05, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 40547.54. The Price to Book ratio for the last quarter was 1.96, with the Price to Cash per share for the same quarter was set at 0.29.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.37. With this latest performance, ZOM shares dropped by -32.82% in over the last four-week period, additionally sinking by -37.70% over the last 6 months – not to mention a rise of 290.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 25.86, with the RSI for the last a single of trading hit 18.05, and the three-weeks RSI is set at 32.21 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.8256, while it was recorded at 0.6749 for the last single week of trading, and 0.8697 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Return on Total Capital for ZOM is now -50.05, given the latest momentum, and Return on Invested Capital for the company is -51.08. Return on Equity for this stock declined to -51.94, with Return on Assets sitting at -48.09. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 2.96. Additionally, ZOM Total Debt to Total Capital is recorded at 2.88, with Total Debt to Total Assets ending up at 2.82. Long-Term Debt to Equity for the company is recorded at 2.13, with the Long-Term Debt to Total Capital now at 1.68.
Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 141.80 and a Current Ratio set at 141.90.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $63 million, or 12.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 40,776,197, which is approximately 110.834% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 17,170,960 shares of the stock with an approximate value of $10.44 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $7.45 million in ZOM stock with ownership of nearly 0.002% of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 84 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 55,992,428 shares. Additionally, 13 investors decreased positions by around 519,009 shares, while 10 investors held positions by with 46,377,724 shares. The mentioned changes placed institutional holdings at 102,889,161 shares, according to the latest SEC report filing. ZOM stock had 64 new institutional investments in for a total of 17,358,796 shares, while 6 institutional investors sold positions of 234,220 shares during the same period.